Differential_JJ
contribution_NN
of_IN
herpes_NN
simplex_NN
virus_NN
type_NN
1_CD
gene_NN
products_NNS
and_CC
cellular_JJ
factors_NNS
to_TO
the_DT
activation_NN
of_IN
human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
provirus_NN
._.

We_PRP
have_VBP
previously_RB
reported_VBN
that_IN
infection_NN
with_IN
herpes_NN
simplex_NN
virus_NN
type_NN
1_CD
-LRB-_-LRB-
HSV-1_NN
-RRB-_-RRB-
activates_VBZ
expression_NN
of_IN
the_DT
human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
-LRB-_-LRB-
HIV-1_NN
-RRB-_-RRB-
provirus_NN
in_IN
T_NN
cells_NNS
._.

Activation_NN
of_IN
the_DT
HIV-1_NN
provirus_NN
correlated_VBD
with_IN
the_DT
activation_NN
of_IN
binding_NN
of_IN
55_CD
-_:
and_CC
85-kDa_JJ
proteins_NNS
to_TO
the_DT
kappa_NN
B_NN
enhancer_NN
and_CC
binding_NN
of_IN
the_DT
50-kDa_JJ
HLP-1_NN
protein_NN
to_TO
the_DT
LBP-1_NN
sequences_NNS
of_IN
the_DT
HIV-1_NN
long_JJ
terminal_JJ
repeat_NN
._.

Further_JJ
examination_NN
of_IN
this_DT
system_NN
has_VBZ
shown_VBN
that_IN
the_DT
inhibition_NN
of_IN
HSV-1_NN
replication_NN
by_IN
the_DT
antiviral_JJ
drug_NN
acyclovir_NN
does_VBZ
not_RB
inhibit_VB
HSV-1-mediated_JJ
induction_NN
of_IN
HIV-1_NN
provirus_NN
._.

Surprisingly_RB
,_,
the_DT
NF-kappa_NN
B_NN
and_CC
HLP-1_NN
binding_NN
activities_NNS
were_VBD
substantially_RB
inhibited_VBN
in_IN
acyclovir-treated_JJ
cells_NNS
._.

In_IN
the_DT
transient-transfection_JJ
assay_NN
,_,
ICP0_NN
,_,
but_CC
not_RB
ICP4_NN
,_,
activated_VBD
the_DT
HIV-1_NN
long_JJ
terminal_JJ
repeat_NN
promoter_NN
region_NN
and_CC
the_DT
effect_NN
of_IN
ICP0_NN
was_VBD
greatly_RB
enhanced_VBN
in_IN
the_DT
presence_NN
of_IN
the_DT
NF-kappa_NN
B_NN
binding_NN
proteins_NNS
,_,
suggesting_VBG
that_IN
induction_NN
of_IN
the_DT
HIV-1_NN
provirus_NN
involves_VBZ
cooperation_NN
between_IN
the_DT
HSV-1-activated_JJ
cellular_JJ
factor_NN
,_,
NF-kappa_NN
B_NN
,_,
and_CC
the_DT
virus-encoded_JJ
transactivator_NN
,_,
ICP0_NN
._.

